EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Non-small-cell lung cancer (NSCLC) is a leading cause of cancer death in patients with human immunodeficiency virus (HIV).
• The impact of specific gene mutations, such as epidermal growth factor receptor (EGFR) and Kirsten ras (KRAS), on NSCLC outcomes in HIV-infected individuals remains largely uncharacterized.
• Understanding these mutations is critical for tailoring treatment strategies in this vulnerable population.

Purpose of the Study:

• To determine the frequency of EGFR and KRAS mutations in NSCLC tumors from HIV-infected patients.
• To evaluate the prognostic and predictive value of these mutations in the context of HIV-NSCLC.
• To inform clinical decision-making and the development of targeted therapies for HIV-NSCLC.

Main Methods:

• Retrospective review of consecutive HIV-NSCLC patients diagnosed between 1996 and 2013 at two Paris university hospitals.
• Tumor samples (n=63) were analyzed for EGFR and KRAS mutational status using molecular techniques.
• Multivariate analysis was performed to assess the impact of mutations and CD4 count on survival.

Main Results:

• EGFR mutations were found in 3.3% of tumors, and KRAS mutations in 11.5% (potentially higher with sensitive techniques).
• Patients with EGFR mutations responded well to tyrosine kinase inhibitors.
• KRAS mutations and low CD4 counts (<200 cells/μL) were significantly associated with poor prognosis (HR 24 and 3.1, respectively).
• Overall survival was >30 months for EGFR mutations, <3 months for KRAS mutations, and 9 months for wild-type tumors.

Conclusions:

• EGFR mutation testing is essential in HIV-NSCLC for its predictive and prognostic significance.
• KRAS mutation is a marker of poor prognosis in this patient group.
• Targeted therapies and specific drug development are warranted for HIV-NSCLC patients based on mutational status.